Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin.
Treatment of seizures in acute intermittent porphyria represents a therapeutic dilemma. Patients needing chronic therapy often experience acute porphyric attacks due to increased hepatic metabolism induced by the antiepileptic drugs themselves. Gabapentin is a new antiepileptic drug not appreciably metabolized by the liver in humans, and it appears to be safe and effective in the maintenance therapy of epilepsy in these patients. We report a patient affected by partial and generalized seizures in the course of acute intermittent porphyria, who was safely and successfully treated with gabapentin.
Zadra
M
M
Divisione di Neurologia, Ospedale Bolognini, Seriate, Italy.
Grandi
R
R
Erli
L C
LC
Mirabile
D
D
Brambilla
A
A
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D017118:Porphyria, Acute Intermittent / Q000150:complications*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin